Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Multiple Doses of TPN672 Tablets Maleate in Patients With Schizophrenia
NCT05192304 is registered in ClinicalTrials.gov with Jiangsu Kanion Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Multiple Doses of TPN672 Tablets Maleate in Patients With Schizophrenia
- Lead sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- February 1, 2022
- Completion date
- March 1, 2024
- Enrollment
- 62 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.